These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37245859)

  • 1. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis.
    Ye X; Chen Y; Qi J; Zhu S; Wu Y; Xiong J; Hu F; Guo Z; Liang X
    Eur J Pharmacol; 2023 Aug; 952():175811. PubMed ID: 37245859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.
    Pan Q; Lin S; Li Y; Liu L; Li X; Gao X; Yan J; Gu B; Chen X; Li W; Tang X; Chen C; Guo L
    EBioMedicine; 2021 Jan; 63():103202. PubMed ID: 33421947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
    Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
    Elife; 2023 Jan; 12():. PubMed ID: 36648330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.
    Yadav P; Khurana A; Bhatti JS; Weiskirchen R; Navik U
    Pharmacol Res; 2022 Oct; 184():106426. PubMed ID: 36075510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
    Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
    Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence.
    Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease.
    Bernsmeier C; Meyer-Gerspach AC; Blaser LS; Jeker L; Steinert RE; Heim MH; Beglinger C
    PLoS One; 2014; 9(1):e87488. PubMed ID: 24489924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis.
    Chen Y; Xu YN; Ye CY; Feng WB; Zhou QT; Yang DH; Wang MW
    Acta Pharmacol Sin; 2022 May; 43(5):1156-1166. PubMed ID: 34934197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D
    Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
    Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease.
    Yabut JM; Drucker DJ
    Endocr Rev; 2023 Jan; 44(1):14-32. PubMed ID: 35907261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
    Tillman EJ; Rolph T
    Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
    Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
    Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease.
    Su X; Kong Y; Peng D
    Clin Chim Acta; 2019 Nov; 498():30-37. PubMed ID: 31419414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
    Zhou D; Chen YW; Zhao ZH; Yang RX; Xin FZ; Liu XL; Pan Q; Zhou H; Fan JG
    Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30510243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Bifari F; Manfrini R; Dei Cas M; Berra C; Siano M; Zuin M; Paroni R; Folli F
    Pharmacol Res; 2018 Nov; 137():219-229. PubMed ID: 30359962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant FGF21 Attenuates Polychlorinated Biphenyl-Induced NAFLD/NASH by Modulating Hepatic Lipocalin-2 Expression.
    Kim HY; Yoo YH
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.